The DOI matches its Crossref record; 130 of the 130 references it cites were found in a registry or an index.
Resistance to Somatostatin Analogs in Acromegaly
Abstract
Somatostatin analogs (SA) are widely used in acromegaly, either as first-line or adjuvant treatment after surgery. First-line treatment with these drugs is generally used in the patients with macroadenomas or in those with clinical conditions so severe as to prevent unsafe reactions during anesthesia. Generally, the response to SA takes into account both control of GH and IGF-I excess, with consequent improvement of clinical symptoms directly related to GH and IGF-I excess, and tumor shrinkage. This latter effect is more prominent in the patients treated first-line and bearing large macroadenomas, but it is also observed in patients with microadenomas, even with little clinical implication. Predictors of response are patients' gender, age, initial GH and IGF-I levels, and tumor mass, as well as adequate expression of somatostatin receptor types 2 and 5, those with the highest affinity for octreotide and lanreotide. Only sporadic cases of somatostatin receptor gene mutation or impaired signaling pathways have been described in GH-secreting tumors so far. The response to SA also depends on treatment duration and dosage of the drug used, so that a definition of resistance based on short-term treatments using low doses of long-acting SA is limited. Current data suggest that response to these drugs is better analyzed taking together biochemical and tumoral effects because only the absence of both responses might be considered as a poor response or resistance. This latter evidence seems to occur in 25% of treated patients after 12 months of currently available long-acting SA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Somatostatin and Its Receptor Family
Patel, Y. C. (1999) · Frontiers in Neuroendocrinology · doi:10.1006/frne.1999.0183 · Cited by 1,648
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0022 · Cited by 1,309
Self-citationMelmed, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra062453 · Cited by 1,160
Reichlin, S. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312153092406 · Cited by 1,044
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Criteria for Cure of Acromegaly: A Consensus Statement
Giustina, A. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.526 · Cited by 987
Rocheville, M., Lange, D. C., Kumar, U., Patel, S. C., Patel, R. C., & Patel, Y. C. (2000) · Science · doi:10.1126/science.288.5463.154 · Cited by 888
Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study1
Orme, S. M., McNally, R. J. Q., Cartwright, R. A., & Belchetz, P. E. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.8.5007 · Cited by 805
Guidelines for Acromegaly Management: An Update
Melmed, S., Colao, A., Barkan, A., Molitch, M., Grossman, A. B., Kleinberg, D., Clemmons, D., Chanson, P., Laws, E., Schlechte, J., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2421 · Cited by 764
Self-citationFactors Influencing Mortality in Acromegaly
Holdaway, I. M., Rajasoorya, R. C., & Gamble, G. D. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031199 · Cited by 651
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
van der Lely, A. J., Hutson, R. K., Trainer, P. J., Besser, G. M., Barkan, A. L., Katznelson, L., Klibanski, A., Herman-Bonert, V., Melmed, S., Vance, M. L., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06844-1 · Cited by 645
Molecular Biology of Somatostatin Receptors*
REISINE, T., & BELL, G. I. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-427 · Cited by 618
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly1
Swearingen, B., Barker, F. G., Katznelson, L., Biller, B. M. K., Grinspoon, S., Klibanski, A., Moayeri, N., Black, P. M., & Zervas, N. T. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.10.5222 · Cited by 586
Determinants of clinical outcome and survival in acromegaly
Rajasoorya, C., Holdaway, I. M., Wrightson, P., Scott, D. J., & Ibbertson, H. K. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03789.x · Cited by 565
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., & Bruns, C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1255 · Cited by 559
Subtypes of the Somatostatin Receptor Assemble as Functional Homo- and Heterodimers
Rocheville, M., Lange, D. C., Kumar, U., Sasi, R., Patel, R. C., & Patel, Y. C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.11.7862 · Cited by 527
Peptides in the Brain: The New Endocrinology of the Neuron
Guillemin, R. (1978) · Science · doi:10.1126/science.212832 · Cited by 485
The Pathophysiological Consequences of Somatostatin Receptor Internalization and Resistance
Hofland, L. J., & Lamberts, S. W. J. (2003) · Endocrine Reviews · doi:10.1210/er.2000-0001 · Cited by 474
Somatostatin in the central nervous system: Physiology and pathological modifications
Epelbaum, J. (1986) · Progress in Neurobiology · doi:10.1016/0301-0082(86)90012-2 · Cited by 466
An audit of outcome of treatment in acromegaly
(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068816 · Cited by 466
A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly
Holdaway, I. M., Bolland, M. J., & Gamble, G. D. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0267 · Cited by 462
Molecular pharmacology of somatostatin receptor subtypes
Patel, Y. C. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03350317 · Cited by 409
Long-Term Mortality after Transsphenoidal Surgery and Adjunctive Therapy for Acromegaly
Swearingen, B. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.10.3419 · Cited by 400
Rubin, J., Ajani, J., Schirmer, W., Venook, A. P., Bukowski, R., Pommier, R., Saltz, L., Dandona, P., & Anthony, L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.600 · Cited by 389
Mestron, A., Webb, S., Astorga, R., Benito, P., Catala, M., Gaztambide, S., Gomez, J., Halperin, I., Lucas-Morante, T., Moreno, B., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510439 · Cited by 387
Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis
Freda, P. U., Katznelson, L., van der Lely, A. J., Reyes, C. M., Zhao, S., & Rabinowitz, D. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0260 · Cited by 346
Ayuk, J., Clayton, R. N., Holder, G., Sheppard, M. C., Stewart, P. M., & Bates, A. S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031584 · Cited by 343
Regulation and function of somatostatin receptors
Olias, G., Viollet, C., Kusserow, H., Epelbaum, J., & Meyerhof, W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02402.x · Cited by 318
Long‐term outcome and mortality after transsphenoidal adenomectomy for acromegaly
Beauregard, C., Truong, U., Hardy, J., & Serri, O. (2003) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2003.01679.x · Cited by 300
Pasireotide (SOM230): Development, mechanism of action and potential applications
Schmid, H. A. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.09.006 · Cited by 290 · cited 16×
“In a single-dose, proof-of-concept study (196), 100 g octreotide and 100 and 250 g SOM230 were given sc to 12 patients with active acromegaly.”
BackgroundResultInfluentialBevan, J. S., Atkin, S. L., Atkinson, A. B., Bouloux, P.-M., Hanna, F., Harris, P. E., James, R. A., McConnell, M., Roberts, G. A., Scanlon, M. F., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-012012 · Cited by 279
Sharma, K. (1996) · Molecular Endocrinology · doi:10.1210/me.10.12.1688 · Cited by 269
A Nationwide Survey of Mortality in Acromegaly
Kauppinen-Mäkelin, R., Sane, T., Reunanen, A., Välimäki, M. J., Niskanen, L., Markkanen, H., Löyttyniemi, E., Ebeling, T., Jaatinen, P., Laine, H., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1381 · Cited by 269
LAMBERTS, S. W. J. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-4-417 · Cited by 265
Cellular biology of somatostatin receptors
Csaba, Z., & Dournaud, P. (2001) · Neuropeptides · doi:10.1054/npep.2001.0848 · Cited by 250
All Five Cloned Human Somatostatin Receptors (hSSTR1-5) Are Functionally Coupled to Adenylyl Cyclase
Patel, Y. C., Greenwood, M. T., Warszynska, A., Panetta, R., & Srikant, C. B. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1088 · Cited by 239
Long-term Treatment of 189 Acromegalic Patients With the Somatostatin Analog Octreotide
Vance, M. L. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400080073013 · Cited by 237
Cozzi, R., Montini, M., Attanasio, R., Albizzi, M., Lasio, G., Lodrini, S., Doneda, P., Cortesi, L., & Pagani, G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2347 · Cited by 228
Jenkins, P. J., Bates, P., Carson, M. N., Stewart, P. M., & Wass, J. A. H. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1616 · Cited by 221
Taboada, G. F., Luque, R. M., Bastos, W., Guimarães, R. F. C., Marcondes, J. B., Chimelli, L. M. C., Fontes, R., Mata, P. J. P., Filho, P. N., Carvalho, D. P., et al. (2007) · European Journal of Endocrinology · doi:10.1530/eje.1.02313 · Cited by 221
Somatostatin receptor subtype gene expression in pituitary adenomas
Miller, G. M. (1995) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.4.1386 · Cited by 220
Murray, R. D., & Melmed, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0027 · Cited by 214
Mercado, M., Borges, F., Bouterfa, H., Chang, T., Chervin, A., Farrall, A. J., Patocs, A., Petersenn, S., Podoba, J., Safari, M., et al. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02825.x · Cited by 214
Freda, P. U., Post, K. D., Powell, J. S., & Wardlaw, S. L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.11.5266 · Cited by 201
Biermasz, N. R., Dekker, F. W., Pereira, A. M., van Thiel, S. W., Schutte, P. J., van Dulken, H., Romijn, J. A., & Roelfsema, F. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032041 · Cited by 193
Colao, A., Attanasio, R., Pivonello, R., Cappabianca, P., Cavallo, L. M., Lasio, G., Lodrini, A., Lombardi, G., & Cozzi, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1208 · Cited by 191
Self-citationCozzi, R., Attanasio, R., Montini, M., Pagani, G., Lasio, G., Lodrini, S., Barausse, M., Albizzi, M., Dallabonzana, D., & Pedroncelli, A. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030110 · Cited by 190
Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors
Panetta, R., & Patel, Y. C. (1994) · Life Sciences · doi:10.1016/0024-3205(94)00956-2 · Cited by 185
Hofland, L. J., van der Hoek, J., van Koetsveld, P. M., de Herder, W. W., Waaijers, M., Sprij-Mooij, D., Bruns, C., Weckbecker, G., Feelders, R., van der Lely, A.-J., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031344 · Cited by 185
Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors
Greenman, Y. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.78.2.398 · Cited by 180
Colao, A. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2779 · Cited by 179
Self-citationMolecular biology of somatostatin receptors
Reisine, T. (1995) · Endocrine Reviews · doi:10.1210/er.16.4.427 · Cited by 179
Taboada, G. F., Luque, R. M., Neto, L. V., Machado, E. D. O., Sbaffi, B. C., Domingues, R. C., Marcondes, J. B., Chimelli, L. M. C., Fontes, R., Niemeyer, P., et al. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0562 · Cited by 174
Florio, T., Morini, M., Villa, V., Arena, S., Corsaro, A., Thellung, S., Culler, M. D., Pfeffer, U., Noonan, D. M., Schettini, G., et al. (2003) · Endocrinology · doi:10.1210/en.2002-220949 · Cited by 169
Sexual dimorphism of the somatotrophic axis
Gatford, K., Egan, A., Clarke, I., & Owens, P. (1998) · Journal of Endocrinology · doi:10.1677/joe.0.1570373 · Cited by 167
Colao, A., Pivonello, R., Auriemma, R. S., De Martino, M. C., Bidlingmaier, M., Briganti, F., Tortora, F., Burman, P., Kourides, I. A., Strasburger, C. J., et al. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02112 · Cited by 167
Self-citationResults of a European Multicentre Study with Sandostatin® LAR® in Acromegalic Patients
Lancranjan, I., Atkinson, A. B., & Sandostatin® LAR® Group# (1999) · Pituitary · doi:10.1023/a:1009980404404 · Cited by 166
Patel, Y. C., Greenwood, M., Kent, G., Panetta, R., & Srikant, C. B. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1412 · Cited by 164
Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
Stewart, P. M., Kane, K. F., Stewart, S. E., Lancranjan, I., & Sheppard, M. C. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.11.3267 · Cited by 161
Freda, P. U. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.11.3808 · Cited by 155
Colao, A., Auriemma, R. S., Galdiero, M., Lombardi, G., & Pivonello, R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0941 · Cited by 147
Self-citationPharmacokinetics of SMS 201-995 in Healthy Subjects
Kutz, K., Nüesch, E., & Rosenthaler, J. (1986) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528609087433 · Cited by 147
Prediction of efficacy of octreotide therapy in patients with acromegaly
Colao, A. A. L., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Sarno, A. D., Longobardi, S., Merola, B., Salvatore, M., & Lombardi, G. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.6.2356 · Cited by 147
Self-citationPresurgical octreotide treatment in acromegaly
Stevenaert, A., Harris, A. G., Kovács, K., et al. (1992) · Metabolism · doi:10.1016/0026-0495(92)90031-5 · Cited by 147
Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patients
Lancranjan, I., Bruns, C., Grass, P. N., Jaquet, P., Jervell, J., Kendall-Taylor, P., Lamberts, S. W. J., Marbach, P., Ørskov, H., Pagani, G. A., et al. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90087-6 · Cited by 145
Arafat, A. M., Möhlig, M., Weickert, M. O., Perschel, F. H., Purschwitz, J., Spranger, J., Strasburger, C. J., Schöfl, C., & Pfeiffer, A. F. H. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2084 · Cited by 145
van der Hoek, J., de Herder, W. W., Feelders, R. A., van der Lely, A. J., Uitterlinden, P., Boerlin, V., Bruns, C., Poon, K. W., Lewis, I., Weckbecker, G., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031052 · Cited by 144
Somatostatin Activation of Mitogen-Activated Protein Kinase via Somatostatin Receptor 1 (SSTR1)
Florio, T., Yao, H. W., Carey, K. D., Dillon, T. J., & Stork, P. A. (1999) · Molecular Endocrinology · doi:10.1210/me.13.1.24 · Cited by 141
Trainer, P. J., Ezzat, S., D'Souza, G., Layton, G. R., & Strasburger, C. J. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03620.x · Cited by 140
Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly
Davies, P. H. O., Stewart, S. E., Lancranjan, I., Sheppard, M. C., & Stewart, P. M. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00389.x · Cited by 137
SASSOLAS, G., Harris, A. G., James-Deidier, A., & THE FRENCH SMS 201–995≌ACROMEGALY STUDY GROUP† (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-391 · Cited by 136
The elucidation of somatostatin receptor functions: A current view
Meyerhof, W. (1998) · Reviews of physiology, biochemistry and pharmacology · doi:10.1007/bfb0000613 · Cited by 129
Melmed, S. K., Cook, D. M., Schopohl, J., Góth, M., Lam, K. S. L., & Marek, J. (2009) · Pituitary · doi:10.1007/s11102-009-0191-1 · Cited by 129
Florio, T. (2007) · Frontiers in bioscience · doi:10.2741/2722 · Cited by 128
Giustina, A., Bonadonna, S., Bugari, G., Colao, A. A. L., Cozzi, R. C., Cannavò, S., Marinis, L. D., Uberti, E. C. D., Bogazzi, F., Mazziotti, G., et al. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0372 · Cited by 128
Self-citationAmato, G., Mazziotti, G., Rotondi, M., Iorio, S., Doga, M., Sorvillo, F., Manganella, G., Salle, F. D., Giustina, A., & Carella, C. (2002) · Clinical Endocrinology · doi:10.1046/j.0300-0664.2001.01438.x · Cited by 126
Alexopoulou, O., Bex, M., Abs, R., T'Sjoen, G. G., Velkeniers, B., & Maiter, D. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2104 · Cited by 121
Maiza, J. C., Vezzosi, D., Matta, M., Donadille, F., Loubes-Lacroix, F., Cournot, M., Bennet, A., & Caron, P. J. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02878.x · Cited by 120
Colao, A. A. L., Cappabianca, P., Caron, P. J., Menis, E. D., Farrall, A. J., Gadelha, M. R., Hmissi, A., Rees, A., Reincke, M., Safari, M., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03441.x · Cited by 116
Self-citationRole of stereotactic radiosurgery in the management of pituitary adenomas
Castinetti, F., Régis, J. M., Dufour, H., & Brue, T. C. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.4 · Cited by 112
Ferrante, E., Pellegrini, C., Bondioni, S., et al. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01191 · Cited by 109
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide
Karavitaki, N., Turner, H. E., Adams, C. B. T., Cudlip, S., Byrne, J. V., Fazal-Sanderson, V., Rowlers, S., Trainer, P. J., & Wass, J. A. H. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03139.x · Cited by 104
Teijeiro, R., Rios, R., Costoya, J. A., Castro, R., Belló, J., Devesa, J., & Arce, V. M. (2002) · Cellular Physiology and Biochemistry · doi:10.1159/000047824 · Cited by 99
Lamberts, S. W. J., Uitterlinden, A. G., SCHUIJFF, P. C., et al. (1988) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1988.tb02890.x · Cited by 99
Zatelli, M. C., Piccin, D., Tagliati, F., Ambrosio, M. R., Margutti, A., Padovani, R., Scanarini, M., Culler, M. D., & Uberti, E. C. D. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021825 · Cited by 94
Pivonello, R., Galderisi, M., Auriemma, R. S., Martino, M. C. D., Galdiero, M., Ciccarelli, A., D’Errico, A., KOURIDES, I. A., Burman, P., Lombardi, G., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1587 · Cited by 93
Self-citationThe Relationship between Serum GH and Serum IGF-I in Acromegaly Is Gender-Specific
Parkinson, C., Ryder, W. D. J., & Trainer, P. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8006 · Cited by 89
Predictors and rates of treatment-resistant tumor growth in acromegaly
BESSER, G. M., Burman, P., & Daly, A. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01968 · Cited by 88
Colao, A., Pivonello, R., Auriemma, R. S., Galdiero, M., Savastano, S., & Lombardi, G. (2007) · European Journal of Endocrinology · doi:10.1530/eje-07-0383 · Cited by 85
Self-citationGender- and age-related differences in the endocrine parameters of acromegaly
Colao, A., Amato, G., Pedroncelli, A. M., Baldelli, R., Grottoli, S., Gasco, V., Petretta, M., Carella, C., Pagani, G. A., Tamburano, G., et al. (2002) · Journal of Endocrinological Investigation · doi:10.1007/bf03345496 · Cited by 81
Self-citationResistance to somatostatin analogs in acromegaly: An evolving concept?
Gola, M., Bonadonna, S., Mazziotti, G., Amato, G., & Giustina, A. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03349183 · Cited by 81
Effects of treatment with octreotide in acromegalic patients—a multicenter Italian study
Arosio, M., Macchelli, S., Rossi, C. M., Casati, G., Biella, O., & Faglia, G. (1995) · European Journal of Endocrinology · doi:10.1530/eje.0.1330430 · Cited by 79
The Novel Somatostatin Ligand (SOM230) Regulates Human and Rat Anterior Pituitary Hormone Secretion
Murray, R. D., Kim, K., Ren, S.-G., Lewis, I., Weckbecker, G., Bruns, C., & Melmed, S. K. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031319 · Cited by 79
Somatostatin Receptors in Pituitary Function, Diagnosis and Therapy
Hofland, L. J., & Lamberts, S. W. J. (2004) · KARGER eBooks · doi:10.1159/000079048 · Cited by 76
Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10‐year follow‐up study
Ronchi, C. L., Attanasio, R., Verrua, E., et al. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03589.x · Cited by 75
Sherlock, M., Fernandez-Rodriguez, E., Alonso, A. A., Reulen, R. C., Ayuk, J., Clayton, R. N., Holder, G., Sheppard, M. C., Bates, A. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1420 · Cited by 74
Chanson, P., Borson‐Chazot, F., Kuhn, J., Blumberg, J., Maisonobe, P., Delemer, B., & the Lanreotide Acromegaly Study Group (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03208.x · Cited by 73
Lombardi, G., Tauchmanovà, L., Somma, C. D., Musella, T., Rota, F., Savanelli, M. C., & Colao, A. (2005) · PubMed · Cited by 73
Self-citationOctreotide Long-Acting Release (LAR): A Review of its Use in the Management of Acromegaly
McKeage, K., Cheer, S. M., & Wagstaff, A. J. (2003) · Drugs · doi:10.2165/00003495-200363220-00014 · Cited by 72
Colao, A., Marzullo, P., Vallone, G., Giaccio, A., Ferone, D., Rossi, E., Scarpa, R., Smaltino, F., & Lombardi, G. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00851.x · Cited by 71
Self-citationSelvarajah, D., Webster, J., Ross, R. J. M., & Newell-Price, J. D. C. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01888 · Cited by 70
Ayuk, J., Stewart, S. E., Stewart, P. M., Sheppard, M. C., & the European Sandostatin LAR Group (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01992.x · Cited by 69
Asa, S. L., Coschigano, K. T., Bellush, L. L., Kopchick, J. J., & Ezzat, S. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64968-1 · Cited by 68
MA, P., WANG, Y., Vanderhoek, J. Y., NEDELMAN, J., SCHRAN, H. F., Tran, L. M., & Lamberts, S. W. J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.04.003 · Cited by 64
Ghigo, E., Biller, B. M. K., Colao, A., KOURIDES, I. A., Rajicic, N., Hutson, R. K., Marinis, L. D., & Klibanski, A. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345774 · Cited by 62
Self-citationGender and Age in the Biochemical Assessment of Cure of Acromegaly
Freda, P. U., Landman, R. E., Sundeen, R. E., & Post, K. D. (2001) · Pituitary · doi:10.1023/a:1015314906972 · Cited by 60
Colao, A. A. L., Marzullo, P., Spiezia, S., Giaccio, A., Ferone, D., Cerbone, G., Sarno, A. D., & Lombardi, G. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6907 · Cited by 52
Self-citationColao, A. A. L., Martino, E., Cappabianca, P., Cozzi, R. C., Scanarini, M., & Ghigo, E. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03349217 · Cited by 48
Self-citationReceptor Isoforms Mediate Opposing Proliferative Effects through Gβγ-Activated p38 or Akt Pathways
Sellers, L. A., Alderton, F., Carruthers, A. M., Schindler, M., & Humphrey, P. P. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.16.5974-5985.2000 · Cited by 48
Use of the oral glucose tolerance test to define remission in acromegaly
Vierhapper, H., Heinze, G., Gessl, A., et al. (2003) · Metabolism · doi:10.1053/meta.2003.50036 · Cited by 44
Casarini, A., Pinto, E. M., Jallad, R. S., Giorgi, R. R., Giannella‐Neto, D., & Bronstein, M. D. (2006) · Journal of Endocrinological Investigation · doi:10.1007/bf03347378 · Cited by 44
Colao, A., Pivonello, R., Cavallo, L. M., Gaccione, M., Auriemma, R. S., Esposito, F., Cappabianca, P., & Lombardi, G. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02584.x · Cited by 44
Self-citationGender and age influence the relationship between serum GH and IGF‐I in patients with acromegaly
Parkinson, C., Renehan, A. G., Ryder, W. D. J., O’Dwyer, S., Shalet, S. M., & Trainer, P. J. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01560.x · Cited by 42
Fedele, M., Martino, I. D., Pivonello, R., Ciarmiello, A., De, M. D. B., Visone, R., Palmieri, D., Pierantoni, G. M., Arra, C., SCHMID, H. A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2505 · Cited by 41
Self-citationBen-Shlomo, A., & Melmed, S. K. (2007) · PubMed · Cited by 40
Tulipano, G., Bonfanti, C., Milani, G., Billeci, B., Bollati, A., Cozzi, R. C., Maira, G., Murphy, W. A., Poiesi, C., Turazzi, S., et al. (2001) · Neuroendocrinology · doi:10.1159/000054651 · Cited by 39
Cervia, D., Petrucci, C., Bluet‐Pajot, M., Epelbaum, J., & Bagnoli, P. (2002) · Neuroendocrinology · doi:10.1159/000064424 · Cited by 36
Dogliotti, L., Tampellini, M., Stivanello, M., Gorzegno, G., & Fabiani, L. (2001) · Annals of Oncology · doi:10.1093/annonc/12.suppl_2.s105 · Cited by 36
Biermasz, N. R., Pereira, A. M., Smit, J. W. A., Romijn, J. A., & Roelfsema, F. (2005) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2005.02.007 · Cited by 33
Cozzi, R. C., Barausse, M., Sberna, M., Lodrini, A., Franzini, A., Lasio, G. B., & Attanasio, R. (2000) · Pituitary · doi:10.1023/a:1012832230598 · Cited by 32
Colao, A. A. L., Pivonello, R., Auriemma, R. S., Galdiero, M., Savastano, S., Grasso, L. F. S., & Lombardi, G. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0424 · Cited by 32
Self-citationAuriemma, R. S., Pivonello, R., Galdiero, M., Martino, M. C. D., Leo, M. D., Vitale, G., Lombardi, G., & Colao, A. A. L. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03345632 · Cited by 29
Self-citationColao, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3754 · Cited by 29
Self-citationColao, A., Pivonello, R., Cappabianca, P., Briganti, F., Tortora, F., Auriemma, R. S., Martino, M. C. D., Marzullo, P., & Lombardi, G. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02351.x · Cited by 25
Self-citationColao, A. A. L., Pivonello, R., Spinelli, L., Galderisi, M., Auriemma, R. S., Galdiero, M., Vitale, G., Leo, M. D., & Lombardi, G. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03346334 · Cited by 23
Self-citationLindsay, J., McConnell, E. M., Hunter, S. J., McCance, D. R., Sheridan, B., & Atkinson, A. B. (2004) · Pituitary · doi:10.1007/s11102-005-1756-2 · Cited by 23
Razzore, P., Colao, A. A. L., Baldelli, R., Gaia, D., Marzullo, P., Ferretti, E., Ferone, D., Jaffrain‐Rea, M., Tamburrano, G., Lombardi, G., et al. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00812.x · Cited by 22
Self-citationCost-effectiveness analysis of somatostatin analogues in the treatment of acromegaly in Brazil
Valentim, J., Passos, V. Q., Mataveli, F. D., & Calabró, A. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000900008 · Cited by 19
The place of pegvisomant in the acromegaly treatment algorithm
Paisley, A. N., Trainer, P. J., & Drake, W. M. (2004) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2004.03.039 · Cited by 8
Cited by
Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., Dekkers, O. M., & _, _. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0796 · Cited by 595
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 556
The Treatment of Cushing's Disease
Pivonello, R., De Leo, M., Cozzolino, A., & Colao, A. (2015) · Endocrine Reviews · doi:10.1210/er.2013-1048 · Cited by 465
Self-citationGadelha, M. R., Bronstein, M. D., Brue, T., Coculescu, M., Fleseriu, M., Guitelman, M., Pronin, V., Raverot, G., Shimon, I., Lievre, K. K., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70169-x · Cited by 396
Self-citationColao, A., Grasso, L. F. S., Giustina, A., Melmed, S., Chanson, P., Pereira, A. M., & Pivonello, R. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0071-6 · Cited by 396
Self-citation
Metadata
- Authors
- Colao, A., Auriemma, R. S., Lombardi, G., & Pivonello, R.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2010-12-01
- Volume
- 32
- Issue
- 2
- Pages
- 247-271
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2158629056
- Cited by
- 257
- References
- 130
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.